The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Myriad Genetics, Inc’s current trading price is -49.62% away from its 52-week high, while its distance from the 52-week low is 0.27%. The stock’s price range for this period has been between $14.72 and $29.30 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 0.69 million for the day, a number notably lower than the average daily volume of 0.79 million over the last three months.
Myriad Genetics, Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $29.30 on 09/18/24, while the lowest value for the same period was recorded at $14.72 on 12/06/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Myriad Genetics, Inc (MYGN) has experienced a quarterly decline of -45.62% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.34B and boasts a workforce of 2700 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 23.82, with a change in price of -12.29. Similarly, Myriad Genetics, Inc recorded 779,703 in trading volume during the last 100 days, posting a change of -45.37%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for MYGN stands at 0.20. Similarly, the long-term debt-to-equity ratio is also 0.18.
MYGN Stock Stochastic Average
As of today, Myriad Genetics, Inc’s raw stochastic average for the last 50 days stands at 3.41%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 8.57%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 26.90% and 32.62%, respectively.
MYGN Stock Price Performance Analysis
Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. Until today this year the stock’s price performance recorded a decrease of -22.88%. However, over the last six months, the performance has been stronger by -33.33%. The price of MYGN decreased -15.99% over the last 30 days. And in the last five days, it has fallen by -9.28%.
